Dual HER2-targeted therapy, particularly the combination of trastuzumab and pertuzumab, has substantially increased pCR rates, subsequently becoming the standard NST regimen for HER2-positive breast cancer [12]. The gene discussed is ERBB2; the disease is breast carcinoma.